Determine the necessary mass, volume, or concentration for preparing a solution.
Olokizumab (anti-IL-6) (Ab170650) - ELISA
Immobilized hu-IL-6 at 1.0 μg/mL can bind Olokizumab (anti-IL-6) (Ab170650) with the EC₅₀ of 102.7 ng/mL.
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Ab170650-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $59.90 | |
Ab170650-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $279.90 | |
Ab170650-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $689.90 | |
Ab170650-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,099.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Product Name | Olokizumab (anti-IL-6) - Primary antibody, specific to IL6, >95%, high purity, Human IgG1 |
---|---|
Synonyms | Anti-IL-6 / IFNb2 Reference Antibody (olokizumab) ; Interleukin BSF 2 antibody; B cell differentiation factor antibody; B cell stimulatory factor 2 antibody; B-cell stimulatory factor 2 antibody; BSF 2 antibody; BSF-2 antibody; BSF2 antibody; CDF antibody |
Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
Specificity | IL6 |
Conjugation | Unconjugated |
Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
Action Type | INHIBITOR |
Mechanism of action | INHIBITOR of Interleukin-6 inhibitor |
Product Description | Olokizumab (anti-IL-6) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA). |
Isotype | Human IgG1 |
---|---|
Light Chain Type | kappa |
SDS-PAGE | 26.1 kDa (Light Chain) & 50.7 kDa (Heavy Chain), under reducing conditions; 167.7 kDa, under non-reducing conditions. |
Purification Method | Protein A purified |
Purity | >95% |
Form | Liquid |
Concentration | Lot by Lot |
Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
Shipped In | Ice chest + Ice pads |
Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS | 1007223-17-7 |
Olokizumab (anti-IL-6) (Ab170650) - ELISA
Immobilized hu-IL-6 at 1.0 μg/mL can bind Olokizumab (anti-IL-6) (Ab170650) with the EC₅₀ of 102.7 ng/mL.
Olokizumab (anti-IL-6) (Ab170650) - SEC
The purity of Olokizumab (anti-IL-6) (Ab170650) is more than 95% verified by HPLC.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IMGT/mAb-DB | 353 |
---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
ZJ23F1001526 | Certificate of Analysis | Nov 02, 2023 | Ab170650 |
ZJ23F1001525 | Certificate of Analysis | Nov 02, 2023 | Ab170650 |
1. Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S et al.. (2014) Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.. MAbs, 6 (3): (774-82). [PMID:24670876] |